References
- Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021 Jan;128(1):89–99 .
- https://www.aao.org/headline/safety-review-committee-releases-report-on-inflamm. [cited 2021 Jun 17].
- Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021 Jul;128(7):1050–1059.
- Study of safety and efficacy of brolucizumab 6 mg dosed every 4 weeks compared to aflibercept 2 mg dosed every 4 weeks in patients with retinal fluid despite frequent anti-VEGF injections (MERLIN). https://clinicaltrials.gov/ct2/show/NCT03710564. [cited 2021 Jun 12].
- https://www.healio.com/news/ophthalmology/20210529/novartis-halts-three-beovu-studies-cites-patient-safety. [cited 2021 Jun 17]
- Iyer PG, Peden MC, Suñer IJ, et al. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep. 2020 Nov 10;20:100989.
- Sharma A, Kumar N, Parachuri N, et al. Brolucizumab and immunogenicity. Eye (Lond). 2020 Oct;34(10):1726–1728.
- Sharma A, Kumar N, Parachuri N, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or occam’s razor? Ocul Immunol Inflamm. 2021 May 20;1-3.
- https://www.ema.europa.eu/en/documents/assessment-report/beovu-epar-public-assessment-report_en.pdf. [cited 2021 Jun 17].
- Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020 Jul;4(4):269–279.
- Efficacy and safety of two different brolucizumab 6 mg dosing regimens in neovascular age-related macular degeneration (FALCON). • FALCON trial will be the key determinant of the impact of initiation of 12 weekly regime on immunogenicity.https://clinicaltrials.gov/ct2/show/NCT04679935. [cited 2021 Jun 17].
- https://www.novartis.com/news/media-releases/novartis-phase-iii-beovu-data-show-potential-fluid-resolution-more-diabetic-macular-edema-patients-fewer-injections-versus-aflibercept. [cited 2021 Jun 17].
- Matsumoto H, Hoshino J, Mukai R, et al. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11:6759.
- Ogura Y, Jaffe GJ, Cheung CMG, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. Published Online First 2021 Jul 22: bjophthalmol-2021-319090. DOI:https://doi.org/10.1136/bjophthalmol-2021-319090.
- Fukuda Y, Sakurada Y, Matsubara M, et al. Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines. 2021;9(9):1164.